---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-146905"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:52:39.470424+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Maravai LifeSciences appoints Rajesh Asarpota as CFO effective June 30, 2025, succeeding Kevin Herde

## Summary
- Rajesh Asarpota appointed EVP and CFO effective June 30, 2025; Kevin Herde transitions to advisory role through Jan 31, 2026.
- Asarpota receives $550k base salary, 70% target bonus, $200k cash sign-on bonus, and equity awards (333,333 options, 500k RSUs, 750k PSUs).
- Previous CFO Kevin Herde entitled to severance payments per May 2023 employment agreement upon signing separation agreement.
- Company not reaffirming or withdrawing FY2025 guidance; will review during Q2 2025 earnings call in August.

## SEC filing metadata
- accession: 0001193125-25-146905
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000119312525146905/0001193125-25-146905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000119312525146905/d32006d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-146905
- JSON: https://secwatch.observer/filing/0001193125-25-146905.json
- Plain text: https://secwatch.observer/filing/0001193125-25-146905.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.